论文部分内容阅读
美国联邦监管机构对仿制药的质量再次亮起红灯。日前,针对一家仿制药生产企业出现的生产违规问题,FDA向对方发出警告函。
The U.S. federal regulators have red lights on the quality of generic drugs again. A few days ago, the FDA issued a warning letter to each other regarding a production violation occurred in a generic drug manufacturer.